Diet drug implicated in depression and suicidality
Posted Thursday 11 February 2010
A group of claimants who were prescribed the diet drug Acomplia (Rimonabant) are bringing proceedings against the manufacturer, Sanofi Aventis, for compensation for depression and suicidal ideation suffered as a result of taking the drug.
Acomplia was withdrawn from the European market in December 2008, following findings that the drug doubled the risk of patients suffering from depression and other psychiatric disorders compared with patients taking a placebo.
If you have suffered similar side effects from Acomplia, and would like information on joining the group action against Sanofi Aventis, please email Bozena Michalowska-Howells at Leigh Day & Co solicitors, or call 0207 650 1200.